clinical trial · NCT04823247
Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - POSITIVE Study
Almirall, S.A.·—·completed·n = 782
Plaque PsoriasisTildrakizumab
brief summary
This is an ethics-approved, multi-national, multi-site Phase IV, 1-cohort prospective observational study. The main purpose of this study is to assess the effect of tildrakizumab on the overall wellbeing in patients with moderate-to-severe psoriasis using the 5-item World Health Organization Wellbeing Index (WHO-5) questionnaire.
started
Nov 22, 2021
primary completion
Jan 9, 2025
completion
Jan 9, 2025
last updated
May 11, 2025
official title
A Multicenter, Prospective Observational RWE Study to Assess Patient-reported Wellbeing Using Tildrakizumab in a Live Setting - POSITIVE Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol